MemoryPlus

About

Funding history · 1 round · — total

Q&A

What is MemoryPlus's primary focus?

MemoryPlus is pioneering an innovative treatment targeting Alzheimer’s-related cognitive decline, leveraging a novel mechanism of action (MOA).

What is the scientific basis for MemoryPlus's research?

MemoryPlus's research is based on groundbreaking work from Prof. Shira Knafo, who discovered that the PTEN protein plays a critical role in memory decline by inhibiting neuronal activity.

How does MemoryPlus's treatment aim to restore memory function?

MemoryPlus aims to restore memory function by disrupting the interaction between PTEN and PDZ domain proteins.

When was MemoryPlus founded?

MemoryPlus was founded in April 2019.

What is MemoryPlus's current employee count?

MemoryPlus has 1-10 employees.

Which sector does MemoryPlus primarily operate in?

MemoryPlus's primary sector is Health Tech & Life Sciences.

What was MemoryPlus's last funding round?

MemoryPlus's last funding round occurred in January 2021, with Israel Biotech Fund as an investor.

What is the current stage of MemoryPlus's product development?

MemoryPlus's product is currently in the R&D stage.

Team · 1

Shira Knafo

Founder · CSO

Sectors & technology

Highlights

Tags